Physician Profile

James K. Aikins Jr., MD, FACOG, FACS

James K. Aikins Jr., MD, FACOG, FACS

    CAR T-Cell Therapy Available at Rutgers Cancer Institute and Robert Wood Johnson University Hospital

    Between 60 to 70 percent of patients with aggressive non-Hodgkin lymphoma are cured with initial chemotherapy and a significant percentage of patients who relapse are cured with a stem cell transplant using the patient’s own cells. However, in patients whose disease becomes resistant to chemotherapy, the average survival is only six months. Until recently, those with B-cell lymphomas that did not respond to standard therapies had limited treatment options.